- Conditions
- Cirrhosis, Liver
- Interventions
- Epigallocatechin gallate (EGCG), Placebo
- Drug · Other
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 627
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatocellular Carcinoma
- Interventions
- CF102, Placebo
- Drug
- Lead sponsor
- Can-Fite BioPharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Dallas, Texas
- Conditions
- Hepatocellular Carcinoma, Cirrhosis
- Interventions
- Usual care, Opt-out, Opt-out + Incentive
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 615 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cirrhosis, Liver
- Interventions
- Care Coordinator Intervention for Direct Intervention Group, Care Coordinator Intervention for Standard of Care Group, Caregiver Intervention
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Non-alcoholic Steatohepatitis, Hepatic Impairment, Cirrhosis
- Interventions
- TVB-2640 - 50 mg
- Drug
- Lead sponsor
- Sagimet Biosciences Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 2
- States / cities
- Orlando, Florida • San Antonio, Texas
- Conditions
- Primary Biliary Cholangitis
- Interventions
- EDP-305 1 mg, EDP-305 2.5 mg, Placebo
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 40
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Coronado, California + 28 more
- Conditions
- Alcohol-related Liver Disease, Liver Diseases
- Interventions
- ENGAGE-ALD Application (APP), Treatment Facilitation bundle, Enhanced Usual Care
- Behavioral
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 268 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Chronic Liver Disease, Cirrhosis, Liver
- Interventions
- Not listed
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Cirrhosis, Hepatitis B, Hepatitis C
- Interventions
- FibroScan
- Device
- Lead sponsor
- Afdhal, Nezam, M.D.
- Individual
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 907 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • St Louis, Missouri • Durham, North Carolina
- Conditions
- Chronic Liver Disease, HepatoCellular Carcinoma, Liver Fibrosis
- Interventions
- Multispectral CT of the liver
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Liver Fibrosis, Liver Inflammation
- Interventions
- Ultrasound-Based Acoustic Radiation Force Impulse (ARFI)
- Device
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Clinically Significant Portal Hypertension
- Interventions
- Placebo, Sorafenib
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 20 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 6
- States / cities
- New Haven, Connecticut • West Haven, Connecticut • Boston, Massachusetts + 3 more
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
- Interventions
- Magnetic Resonance Elastography (MRE), Liver biopsy
- Other · Diagnostic Test
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 2
- States / cities
- La Jolla, California • Madison, Wisconsin
- Conditions
- Adult Liver Carcinoma, Liver Cirrhosis
- Interventions
- 18F-Fluoromisonidazole, Arterial Embolization, Computed Tomography, Positron Emission Tomography
- Drug · Procedure · Diagnostic Test
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Advanced Chronic Liver Disease, Healthy Participants
- Interventions
- AZD2389, Quinidine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland
- Conditions
- Metabolic Associated Fatty Liver Disease, Metabolic Associated Steatotic Liver Disease, Cirrhosis, Liver, NASH, Liver Fibrosis, Liver Fat, Liver Steatoses, Liver Inflammation
- Interventions
- Not listed
- Lead sponsor
- Foundation for the National Institutes of Health
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 400 participants
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Miami, Florida • Columbus, Ohio • Bellaire, Texas + 1 more
- Conditions
- Obesity, Liver Diseases, Liver Fibrosis, Liver Fat, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD, MASH, Weight Loss, Insulin Resistance, Insulin Sensitivity, Insulin Sensitivity/Resistance, Metabolic Disease, Diabetes, Diabetes Mellitus, Type 2, NASH With Fibrosis, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non-alcoholic Steatohepatitis
- Interventions
- ESG + lifestyle modification, Lifestyle modification
- Device · Behavioral
- Lead sponsor
- Pichamol Jirapinyo, MD, MPH
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Morgantown, West Virginia
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Seladelpar, PTM Seladelpar, Cilofexor Dose B, PTM Cilofexor Dose A, PTM Cilofexor Dose B, Cilofexor Dose A
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 4
- States / cities
- Colorado Springs, Colorado • Lakewood Rch, Florida • Atlanta, Georgia + 1 more
- Conditions
- Cirrhotic Cardiomyopathy
- Interventions
- Not listed
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee • Dallas, Texas
- Conditions
- Liver Disease Chronic, End Stage Liver DIsease, Cirrhosis, Cirrhosis, Liver, Advanced Cirrhosis
- Interventions
- LiverPAL
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cirrhosis, Liver, End Stage Liver DIsease, Acute Kidney Injury, Liver Transplant; Complications
- Interventions
- Angiotensin II, Norepinephrine
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Cirrhosis, Spontaneous Bacterial Peritonitis
- Interventions
- doxycycline
- Drug
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 841 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Saroglitazar magnesium 1 mg, Placebo
- Drug
- Lead sponsor
- Zydus Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 3
- States / cities
- Marietta, Georgia • Indianapolis, Indiana • Houston, Texas
- Conditions
- Hepatocellular Carcinoma, Cirrhosis, Liver
- Interventions
- Tremelimumab, Durvalumab
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- San Antonio, Texas